Moderna and Merck now have the first positive Phase 3 result for an individualized mRNA cancer therapy. Their intismeran and Keytruda combination met both recurrence and metastasis endpoints in resected melanoma. The signal matters, but the size of the benefit is still hidden.
Britain does not lack ideas for social care funding. It lacks a durable way to spread a large, uncertain cost across the population. Andy Burnham’s case for a universal service sharpens the issue, but private finance cannot make care risk disappear.
Novartis gave health investors a clean case study in the patent cliff problem on July 21, 2026. Sales grew again in Q2, but the route was not smooth. New medicines had to run hard just to offset copycat pressure on older blockbusters.